Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.
July 14, 2026 04:43 PM EDT
PharmaFDA+
Celcuity wins approval for breast cancer drug Revtorpyk
Nicole DeFeudis
A small public biotech won approval for a breast cancer drug that was designed to improve on similar treatments from Novartis and Roche.
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s…
Celcuity's Revtorpyk wins FDA approval but won't launch until late Q3, sending shares down 14% as analysts expected a faster…
The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk,…
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a…
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that…
Revtorpyk was approved for women with advanced breast cancer whose disease worsened after previous hormone-based treatments;…
Celcuity gains FDA approval for closely watched breast cancer drug
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
FDA approves breast cancer drug that cut progression risk by 76%
Correction to Celcuity Gets FDA Approval Headline
Celcuity's breast cancer drug approved, its first
FDA grants traditional approval to Retevmo for RET fusion-positive solid tumors
PAM Inhibitor Approved for HR-Positive Breast Cancer
FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time
